In patients with known ROS1 G2032R, ORR was 65% (11/17) with a median duration of response (mDOR) of 15.8m (6, NE) among repo-naïve patients and ORR was 38% (3/8) among repo-pretreated patients.

Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles Sep. 09, 2024 6:30 AM ET Nuvalent ...

Outcomes With Local Therapy and Tyrosine Kinase Inhibition in Patients With ALK/ROS1/RET-Rearranged Lung Cancers – An ASCO Reading Room selection December 23, 2022 ...

Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor, Neladalkib, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2025 Provided by PR Newswire Mar 25, 2025, 9:24: ...

ASCO > Lung Cancer Update on Treatment Tactics in ALK/ROS/RET-Rearranged NSCLC — Thoughts from Alessandra Bearz, MD, Anne-Marie C. Dingemans, MD, PhD, and Sanjay Popat, MBBS, PhD ...

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read why I'm bearish on NUVL stock here.

Rapid enrollment in Phase 2 portions of the ARROS-1 and ALKOVE-1 clinical trials; Pivotal data from both ROS1 and ALK programs now anticipated in 2025 Initiation of ALKAZAR Phase 3 randomized ...

This summer’s phase III news from Qilu Pharmaceutical Co. Ltd. with iruplinalkib – an oral inhibitor of ALK and ROS1 tyrosine kinase – reinforced an ongoing interest in the pair of oncology targets, ...

Since ROS1 is structurally related to ALK, ROS1 fusion proteins can be targeted by agents that also inhibit ALK; crizotinib and entrectinib have been used in this context.

For ROS1, it’s important to note that not all these ALK inhibitor agents have ROS1 coverage. For instance, alectinib does not cover ROS1.